Ownership Summary
Xilio Therapeutics, Inc. (NASDAQ:XLO) has 1 institutional investors that have filed 13F reports for the period ending March 2026.
- These investors collectively held 4.0% of Xilio Therapeutics's outstanding shares in March 2026, down from 33.9% in December 2025.
- Their total shares held in XLO decreased -0.0% from the prior quarter, while the number of investors in Xilio Therapeutics decreased 97.22% year over year.
- Of these 1 funds, 0 grew their exposure to Xilio Therapeutics, 1 cut back, and 0 maintained positions.
- In total, institutional investors held 650.39K shares in Xilio Therapeutics as of March 2026, down by 0 shares quarter on quarter, and down 958.77K shares year over year.
- Gilead Sciences, Inc. holds the largest position in XLO at 650.39K shares as of March 31, 2026, or 3.98% of shares outstanding.
- The largest sellers of Xilio Therapeutics for the quarter ending March 2026 were Gilead Sciences, Inc. (0).
- Xilio Therapeutics's 1 largest shareholders as of March 2026 include Gilead Sciences, Inc. (650.39K) per Business Quant data.